Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.45 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6859063 | 0.98 | LMNA (0.48) | LMNAGPR84FFAR1MAPTLCK | |
| SCHEMBL6853532 | 0.96 | LMNA (0.48) | LMNAGPR84FFAR1MAPTLCK | |
| SCHEMBL6861932 | 0.94 | LMNA (0.45) | LMNAGPR84FFAR1MAPTLCK | |
| SCHEMBL6860417 | 0.89 | CA2 (0.46) | LMNAGPR84FFAR1MAPTLCK | |
| SCHEMBL11458719 | 0.83 | ALDH1A1 (0.52) | CA2CA1 | |
| SCHEMBL28683257 | 0.83 | LMNA (0.52) | LMNAGPR84FFAR1MAPTLCK | |
| SCHEMBL28131455 | 0.82 | GPR84 (0.53) | LMNAGPR84FFAR1MAPTLCK | |
| SCHEMBL28575196 | 0.81 | CA2 (0.48) | LMNAGPR84CA2FDPSCA1 | |
| SCHEMBL9142345 | 0.81 | ACE2 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL17002061 | 0.81 | GPR84 (0.68) | GPR84FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754862-B2 | Multi-chromophoric AZO pyridone colorants | XEROX CORPORATION (US) | 2010-07-13 | — | — | US | disclosed |
| US-7381253-B2 | Multi-chromophoric azo pyridone colorants | XEROX CORPORATION (US) | 2008-06-03 | — | — | US | disclosed |
| US-20080071051-A1 | MULTI-CHROMOPHORIC AZO PYRIDONE COLORANTS | XEROX CORPORATION (US) | 2008-03-20 | — | — | US | disclosed |
| US-20060117991-A1 | Phase change inks; piezoelectric printing | XEROX CORPORATION | 2006-06-08 | — | — | US | disclosed |
| US-6755902-B2 | YELLOW DYE; THERMAL STABILITY; LIGHTFASTNESS; SOLUBILITY; SHARP DURABLE IMAGES; NONCLOGGING | XEROX CORPORATION | 2004-06-29 | — | — | US | disclosed |
| US-6696552-B2 | AMIDATION BETWEEN PRIMARY AMINE AND ESTER HAVING ELECTRON WITHDRAWING FUNCTIONALITY; CYCLIZATION WITH KETO ESTER | XEROX CORPORATION | 2004-02-24 | — | — | US | disclosed |
| US-20040007155-A1 | Phase change inks containing azo pyridone colorants | XEROX CORPORATION | 2004-01-15 | — | — | US | disclosed |
| US-20040006234-A1 | PROCESS FOR PREPARING SUBSTITUTED PYRIDONE COMPOUNDS | XEROX CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-6673139-B1 | Phase change inks containing dimeric azo pyridone colorants | XEROX CORPORATION | 2004-01-06 | — | — | US | disclosed |
| US-6646111-B1 | Phase change inks | XEROX CORPORATION | 2003-11-11 | — | — | US | disclosed |
| US-6590082-B1 | Color materials used as inks in phase change recording and dyeing of textiles, high spectral emmitance chromogens, electronics, optical and color filters | XEROX CORPORATION | 2003-07-08 | — | — | US | disclosed |
| US-6576748-B1 | Diazotizing dianiline compound; salt formation, coupling, desalting; reaction with pyridone or dipyridone compound | XEROX CORPORATION | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060117991-A1 | Phase change inks; piezoelectric printing | RB1, CDKN1A, RCC1 | LMNA 1205/4885GPR84 4445/4885FFAR1 4766/4885 |
| US-20040006234-A1 | PROCESS FOR PREPARING SUBSTITUTED PYRIDONE COMPOUNDS | PDXK, DPYD, RRM2B | LMNA 1206/4885GPR84 4329/4885FFAR1 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.